Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

about

Erratum to: Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

P921

Q44526860-8775DD78-3F5D-4763-ACC4-3A3DEB9E46CD

P921

Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

Item

http://www.wikidata.org/entity/Q38795404

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treating the Underlying Pathop ...... Advances and Future Prospects.

@en

type

Item

label

Treating the Underlying Pathop ...... Advances and Future Prospects.

@en

prefLabel

Treating the Underlying Pathop ...... Advances and Future Prospects.

@en

P1476

Treating the Underlying Pathop ...... Advances and Future Prospects.

@en

P2093

Hoda Gheitasi

http://www.w3.org/2001/XMLSchema#string

Pilar Brito-Zerón

http://www.w3.org/2001/XMLSchema#string

Soledad Retamozo

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum to: Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

P2860

Clinical development of gene therapy: results and lessons from recent successes

Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis

Advances in salivary gland gene therapy - oral and systemic implications

Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial

T cell epitope mimicry between Sjögren's syndrome Antigen A (SSA)/Ro60 and oral, gut, skin and vaginal bacteria.

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.

Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse.

Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.

Endocrine alterations in primary Sjogren's syndrome: an overview.

P2888

s40265-016-0659-z

P304

1601-1623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-016-0659-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manuel Ramos-casals

P577

2016-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024706115

http://www.w3.org/2001/XMLSchema#string

P698

27844414

http://www.w3.org/2001/XMLSchema#string

Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

about

P921

P921

Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2507

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2507

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698